



Corporate presentation

公司报告

May 2022
2022年5月

Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to the timing, completion and delivery of data from clinical studies, the effectiveness of Volition’s blood-based diagnostic and prognostic tests as well as Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic or prognostic tool for COVID-19. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic or prognostic products Volition might develop; Volition’s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to “\$” refer to the legal currency of the United States of America.


An introduction... / 公司介绍

Our mission is
to **save** lives and
improve outcomes
for millions of
people worldwide. /
我们的使命是**拯救**生
命和**改善**全世界数百
万人的健康状况。

- We are a leading epigenetics company / 我们是一家领先的表观遗传学公司
- We are dedicated to advancing the science of epigenetics through our patented Nucleosomics™ platform. / 我们致力于通过我们获得专利的Nucleosomics™平台推动表观遗传学的发展。
- We aim to revolutionize the diagnosis and monitoring of life-altering diseases, through low cost routine blood tests. / 我们的目标是通过低成本的常规血液测试，彻底改变对生命有重大影响的疾病的诊断和监测。
- 90 patents granted with more than 100 additional patents pending / 获得了90项专利，另有100多项专利待批
- Early stages of our commercialization BUT tremendous commercial opportunity. / 我们商业化处于早期阶段，但是有巨大的商业机会

Revenue vs Number of Tests / 收入对比检测数量*

Revenue
Opportunity
(\$mn) / 收入
机会(\$百万)



*Not revenue or margin guidance. Based on averages across all products / 不是收入或利润指引。基于所有产品的平均值

Early diagnosis saves lives / 早期诊断拯救生命

nu·Q

Imagine a world where diseases like cancer and sepsis can be diagnosed **early** and monitored easily using **routine** blood tests. / 想象一下，在这个世界上，像癌症和败血症这样的疾病可以早期诊断，并通过常规血液测试轻松监测。

That's the world we're trying to build by developing our ground-breaking family of **simple, low-cost** Nu.Q® tests. / 这就是我们通过开发**简单、低成本的**突破性Nu.Q®测试系列所要建立的世界。

nu·Q

nu·Q

nu·Q

vet


capture

nu·Q
nets


nu·Q
discover

Nu.Q® - the basic concept (across species)

Nu.Q® - 基本概念（跨物种）



- Every 150 base pairs of DNA are wrapped around a nucleosome to form a DNA-Nu complex / 每隔150个碱基对的DNA包裹在核小体周围，形成DNA-Nu复合体。
- Each individual bead is called a nucleosome / 每个单独的珠子称为核小体。
- Nucleosomes consist of DNA and histone proteins. Histones and DNA are subjected to a variety of **epigenetic modifications** / 核小体由DNA和组蛋白组成。组蛋白和DNA受到多种**表观遗传修饰**。
- **Cancer leads to cell death which results in fragmentation and release of nucleosomes into the blood** / **癌症导致细胞死亡，从而导致核小体碎裂并释放到血液中。**
- Nu.Q® assays quantify nucleosomes from different origins e.g. cancer versus healthy using simple immunoassay, mass spectrometry, and/or sequencing. / Nu.Q®分析可量化来自不同来源的核小体，例如使用简单的免疫测定、质谱和/或测序技术可将癌症与健康进行比较。



How will Nu.Q® make a difference? / Nu.Q®将如何发挥作用?

Our Nu.Q® tests detect various characteristic changes in nucleosomes that occur from the **earliest** stages of disease. / 我们的Nu.Q®检测可以检测出疾病**最早期**阶段的核小体的各种特征性变化。



Population
screening / 人口筛查



Risk stratification &
diagnostic aid / 风险
分级和诊断辅助



Disease and
treatment monitoring
/ 疾病和治疗监测

How can our Nu.Q® tests be used? / 我们的Nu.Q® 测试如何使用?



Early detection of canine cancer / 早期检测犬类动物癌症
Disease response and progression monitoring / 疾病反应和病情发展监测



Detection, risk stratification and monitoring of NETosis (in sepsis and COVID-19) / NETosis (在败血症和COVID-19) 的检测、风险分层和监测



Early detection of blood, lung, colorectal and other human cancers. / 血液、肺、结直肠和其他人类癌症的早期检测
Disease and treatment monitoring of blood cancers. / 血癌的疾病和治疗监测




An enabling technology in the liquid biopsy space, to capture and concentrate nucleosomes containing particular epigenetic signals for further analysis, more accurate diagnosis and to guide treatment. / 液体活检领域的一项激活技术，可以捕获和浓缩含有特殊表观遗传信号的核小体，以便进一步分析、更准确地诊断和指导治疗。



Nu.Q[®] Vet Cancer Test / Nu.Q[®]动物癌症检测

Our Product Proposition / 我们产品的定位



- The **Nu.Q® Vet Cancer Test** is positioned for use in the annual health check of older dogs (those that are seven years and older) and may also be a complementary test for younger dogs at high risk for developing cancer in their lifetimes such as Golden Retrievers / **Nu.Q®动物癌症筛查检测**被定位为用于老年狗（7岁及以上）的年度健康检查，也可以是对金毛寻回犬等一生中患癌风险较高的年轻狗的一种补充检测。
- It is a **simple, low-cost, easy to use** ELISA based screening blood test which will help streamline the diagnostic process for up to 1/3rd of malignancies in dogs namely Lymphoma and Hemangiosarcoma. / 它是一种**简单、低成本、易于使用**的基于ELISA的血液筛查检测，将有助于简化多达1/3的狗恶性肿瘤的诊断过程，即淋巴瘤和血管肉瘤。
- In a study of over 330 dogs, at **97%** specificity, the Nu.Q® Vet Cancer Test identified **77%** of lymphomas and **82%** of hemangiosarcoma versus control^{1,2}. / 在一项针对330多只狗的研究中，在**97%**的特异性下，与对照组相比，Nu.Q®动物癌症筛查检测确定了**77%**的淋巴瘤和**82%**的血管肉瘤^{1,2}。
- It is available from the GI Lab at Texas Results due 3-5 business days / 在德克萨斯州的GI Lab可进行检测，3-5个工作日可出结果

1. 2017-1018 AVMA Pet Ownership and Demographics SourceBook
2. <https://fetchacure.org/resource-library/facts//>
3. <https://gco.iarc.fr/today/data/factsheets/populations/840-united-states-of-america-factsheets.pdf>





Volition Veterinary / Volition兽医

Commercial Strategy / 商业策略

- **Partner with established veterinary diagnostic companies to market, sell, and process our test / 与成熟的兽医诊断公司合作，营销、销售和我们的检测产品。**
- Leveraging their networks and expertise / 利用他们的网络和专业知识
- Multi-platform (external lab and point-of-care) / 多平台（外部实验室和护理点）
- Joint tech transfer / 联合技术转让

Two underlying principles: / 两个基本原则：

- Low CapEx for partners / Low OpEx for Volition / 合作伙伴资本开支低/ Volition运营开支低
- Accessible worldwide / 可在全球范围内使用

Global Licensing & Supply Agreement / 全球 许可和供应协议

Global Licensing & Supply Agreement / 全球许可和供应协议

Heska

- is a leading global provider of advanced veterinary diagnostics (Top Four) / 是一家全球领先的先进兽医诊断技术供应商（排名前四）。
- one of the most innovative on the Point of Care / 护理点上最具创新性的公司之一
- has a worldwide distribution and partnering network. / 拥有一个全球性的分销和合作网络。
- entrepreneurial culture / 企业家文化

Subset of the Veterinary Diagnostics Market – **Cancer for companion animals** / 兽医诊断市场的分支—宠物的癌症

Our executed agreement provides **Heska**: / 我们执行的协议为Heska提供:

- **Exclusive rights** to sell Volition's Nu.Q[®] Vet Cancer Test for companion animals at the point of care. / 针对护理点的宠物，**独家销售**Volition的Nu.Q[®]动物癌症测试的权利
- **Non-exclusive** rights to sell the Nu.Q[®] Vet Cancer Test for companion animals via Heska's reference laboratories and, / 针对在Heska的参比实验室的宠物，**非独家销售**Nu.Q[®]动物癌症测试的权利
- **Exclusive rights** to canine cancer monitoring and feline lymphoma tests at the point of care. / 在护理点犬类癌症监测和猫科动物淋巴瘤检测的独家权利

Our executed agreement provides **Volition**: / 我们执行的协议为**Volition**提供:

- \$10 million upfront payment (received Q1 2022) / \$1000万首付款（2022年第一季度已收到）
- Up to \$13 million in milestone payments (expected 2022-23) / 最高\$1300万里程碑付款（预计2022年至2023年支付）
- Further \$5 million milestone payment (expected 2024) / 另外\$500万里程碑付款（预计2024年支付）
- **ongoing payment** for kits and key components (for both reference lab and POC) / **持续支付**成套设备和关键部件（用于参比实验室和护理点）的费用

EVERY TIME Heska sells a test Volition will make money / Heska每卖出一份测试产品，Volition都会赚钱。

What's next? / 未来规划

- More global and regional licensing agreements expected / 预计会有更多的全球和区域许可协议
- Drive accessibility - aim to grow our veterinary market coverage to / 推动可及性 – 目标是将我们的兽医市场覆盖率提高到
 - 90% in the U.S. within 12 months, / 12个月内在美国达到90%
 - EU to 35% / 欧盟达到35%
 - Asia building the plan / 亚洲构建计划
- Expect **significant revenue at high gross margins** with current product.... / 以目前的产品，预计在高毛利的情况下会有大量的收入
- VVDD will become a significant revenue contributor for Volition. / VVDD 将成为Volition的一个重要收入贡献者

Our Product Pipeline / 我们的产品管线

	Today / 当前	Q3 22 / 2022 年第三季度	Q4 22 / 2022年第 四季度	2023
Dogs / 狗	Cancer Screening / 癌症筛查 <ul style="list-style-type: none"> • Lymphoma / 淋巴瘤 • Hemangiosarcoma / 血管肉瘤 	Expansion of cancers detected / 扩大癌症检测范围	Cancer Monitoring / 癌症筛查 <ul style="list-style-type: none"> • Treatment Response / 治疗反应 • Remission / 缓解 	POC Test / 护理点检测

Longer Term Products in Development

正在开发的长期产品


Cancer
in Cats /
猫的癌症

NETosis

Production
Animals /
生产型动物

Elite
Equestrian
/ 马类疾病

Nu.Q® Vet Cancer Test Opportunity Simulation* / Nu.Q®动物癌症检测机会模拟



Current Focus Areas

当前重点领域




**Monitoring the immune system to
save lives. / 监测免疫系统以拯救生命**



Developing a diagnostic solution for NETosis / 开发NETosis的诊断解决方案



An abnormal immune response / 异常的免疫反应



What is NETosis? / 什么是NETosis ?

- During infection, white cells migrate to the infected tissue to engulf invading pathogens and to produce antibodies against them. / 在感染期间，白细胞迁移到受感染的组织，吞噬入侵的病原体并产生针对它们的抗体。
- In addition, white cells called neutrophils unwind their chromosomes and eject chromatin material, consisting of strings of nucleosomes, out of the cell to form NETs (Neutrophil Extracellular Traps). / 此外，被称为中性粒细胞的白细胞展开其染色体，并将由成串的核小体组成的染色质材料弹出细胞，形成NETs（中性粒细胞胞外陷阱）
- Bacteria and viruses become trapped in the NETs and are killed by cytotoxic proteins. / 细菌和病毒被困在NETs中，并被细胞毒性蛋白杀死
- However, excessive production of NETs can damage the tissue and lead to the formation of potentially dangerous minute blood clots called microthrombi. / 然而，NETs的过度生产会损害组织，并导致形成潜在的危险的微小血块，即微血栓
- Sepsis & severe COVID-19 are caused by excessive production of NETs. / 过度产生NETs引起败血症和严重的新冠病毒症状。

The ejected NETs can be measured using Volition's Nu.Q® nucleosome assays. / 喷出的NETs可以用Volition的Nu.Q®核小体检测法进行测量

NETs Update / NETs最新进展



- **Wide applicability** for monitoring diseases with a NETs component (e.g.COVID-19, influenza, sepsis, autoimmune diseases & cancer) / 广泛适用于监测含有NETs成分的疾病（如COVID-19、流感、败血症、自身免疫性疾病和癌症）
- Data published show that the level of circulating NETs, as measured using our Nu.Q® NETs assays, **correlates** with current disease severity and mortality in COVID-19 patients. / 已公布的数据显示，使用我们的Nu.Q® NETs检测法测量的循环NETs水平与COVID-19患者目前的疾病严重程度和死亡率有关
- In addition, the studies show that our NETs-based tests could be used **to predict** future disease severity and guide treatment selection in patients, on admission. / 此外，这些研究表明，我们基于NETs的测试可用于预测未来疾病的严重程度，并指导患者在入院时的治疗选择
- **CE Mark** for first NETs product, across multiple platforms, expected by summer 2022 / 预计到2022年夏季，首个跨平台的NETs产品将获得CE认证。
- Plan to register with broad '**CRP style**' claim “for the detection and evaluation of infection, tissue injury, inflammatory disorders and diseases associated with NETosis”. / 计划以广泛的“CRP风格”注册，声称“用于检测和评估感染、组织损伤、炎症性疾病和与NETosis有关的疾病”。
- Product Manager in place / 产品经理已经到位
- Developing U.S. study plan geared toward FDA approval / 制定面向FDA批准的美国研究计划

Developing a diagnostic solution for NETosis / 正在开发NETosis的诊断解决方案



- Working with [Santersus](#) – technology cleanses blood of NETs as treatment for sepsis / 与 [Santersus](#) 合作 - 清洗血液中的NETs的技术，作为败血症的治疗方法
- Animal study using Nu.Q® NETS to monitor treatment response to their developmental plasmapheresis treatment published / 发表了使用Nu.Q® NETS监测其发展性血浆疗法的治疗反应的动物研究
 - It demonstrated that Nu.Q® is an effective method for monitoring Santersus' highly selective plasmapheresis treatment targeting NETs in sepsis¹. / 它表明Nu.Q®是一种有效的方法，可以监测Santersus针对败血症中NETs的高选择性血浆透析治疗。
- Santersus embarking on next phase of studies, using Volition's Nu.Q® assays to monitor treatment response, including their first human trial. / Santersus正着手进行下一阶段的研究，使用Volition的Nu.Q®检测方法来监测治疗反应，包括他们的第一个人体试验。

1. [Therapeutic Removal of NETs from Blood in a Pig Model of Sepsis. E-ISFA conference A. Aswani³, 2, D. Genkin², P. Skorup⁴, J. Micallef¹, M. Wargnies¹, R. Varsebroucq¹, M. Lipcsey](#)

Developing a diagnostic solution for NETosis / 正在开发NETosis的诊断解决方案

- Given broad range of potential use case settings for Nu.Q® NETs, currently driving forward commercialization plans. / 鉴于Nu.Q® NETs的潜在用途范围广泛，目前正在推动商业化计划。
- Product Manager appointed / 已经任命产品经理
- Aim to launch a CE Marked Nu.Q® NETs product later this year, across multiple platforms, followed by FDA approval. / 争取在今年晚些时候在多个平台上推出获得CE认证的Nu.Q® NETs产品，随后获得美国食品药品监督管理局的批准。
- Developed a Clinical Study and Regulatory plan including FDA. / 制定了一个临床研究和监管计划，包括美国食品药品监督管理局。



Clinical & Regulatory Strategy / 临床和监管策略

Clinical and Regulatory Program Europe / 欧洲的临 床和监管项目

Platform / 平台		Clinical Target / 临床目标	CE Marking / CE认证标志	Clinical Validation Studies / 临床验证研究
Manual / 手动	ELISA	NETosis	May 2022 / 2022年5月	H2 2022 / 2022年下半年
Automated I / 自动I	ChLIA	NETosis	May 2022 / 2022年5月	H2 2022 / 2022年下半年
Automated II / 自动II	HIA	NETosis	TBD / 待定	TBD / 待定

Clinical and Regulatory Program U.S. / 美国的临床和监管项目

Platform / 平台	Clinical Target / 临床目标	FDA	Target Submission / 目标提交	FDA Feedback / FDA反馈	Clinical Validation Study / 临床验证研究	Approval / 批准
Automated II / 自动II	Sepsis / 败血症	BDDR*	Q4 2022 / 2022年第四季度	70 Days / 70天	~2 years / 约两年	1 year / 一年
Automated I / 自动I	NETosis	510k pre sub	H1 2023 / 2023年上半年	TBD / 待定	~2 years / 约两年	TBD / 待定

***BDDR – Breakthrough Device Designation Request / 突破性医疗器械资格认定**

What sets us apart? / 是什么让我们与众不同?

Our **key** differentiator is our Intellectual Property /

我们的关键与众不同之处是我们的知识产权

- Our patent portfolio is growing / 我们的专利组合正在增长¹
- Our products are protected until at least 2031 including animal diagnostics / 我们的产品受保护至少到2031年，包括动物诊断法
- Further breakthrough patents ongoing / 不断取得突破性专利

102
patents
pending
worldwide /
全球有102项
专利正在申请
中

63 additional
patents granted
worldwide in
growing IP
portfolio / 全球范
围内不断增长的知
识产权组合，获授
63项专利

12 patents
granted in
the U.S. / 在
美国获得了
12项专利

32 patent
families / 32
个专利家族

(including 3 in-licensed)
/ (包括三个引进的)

15 patents
granted in
Europe / 在
欧洲获得15
项专利


Total Addressable Market / 总的潜在市场规模

\$70 billion / \$ 700亿*

*subject to fluctuations based on numerous assumptions, which, if prove incorrect could materially impact our estimations and results. / * 数据可能波动。基于许多假设，如果假设被证明是错误的，可能对我们的估计和结果产生重大影响。

Revenue vs Number of Tests / 收入对比检测数量*

Revenue
Opportunity
(\$mn) / 收入
机会 (\$百万)



*Not revenue or margin guidance. Based on averages across all products / 不是收入或利润指引。基于所有产品的平均值

Priorities / 优先事项

Focus on driving revenue in the following areas: / 专注于推动以下领域的收入:

- Licensing of its technology, with a particular but not exclusive focus on Nu.Q® Vet. / 其技术的许可，特别是但不限于Nu.Q® Vet
- Complete Heska Corporation agreement milestones in order to receive further milestone payments. / 完成Heska Corporation的协议里程碑，以便获得进一步的里程碑付款
- Sales of key components of Point of Care test with Heska. / 与Heska一起销售护理点检测的关键部件
- Sales of kits from non-exclusive agreements for the use of Nu.Q® Vet via central reference labs. / 根据非独家协议，通过中央参比实验室销售Nu.Q® Vet的试剂盒
- Ongoing and new Nu.Q® Discover agreements. / 持续的和新的Nu.Q® Discover协议
- Sales of its disease monitoring tests (e.g. sepsis, COVID-19). / 销售其疾病监测测试（如败血症、COVID-19）

Key Financials Q1 2022 / 关键财务数据，2022年第一季度

NYSE American: **VNRX**

Market Cap: \$142.01m / 市值: \$1.4201亿*

52-week range: \$2.38-\$4.14 / 52周价格区间: \$2.38-\$4.14 *

Monthly Burn: Approx. \$2m / 每月资金消耗: 约\$200万**

Cash-on-hand: ~\$23.7m / 手中现金: 约\$2370万**

* As of May 9th,
2022 / 截止2022年5
月9日

**Q1 2022 / 2022年
第一季度
As of March 31,
2022 / 截止2022年3
月31日

Executive Team



Dill Faulkes PhD, Executive Chairman - Dill Faulkes has over 30 years of entrepreneurial and managerial experience as the founder and CEO of several software companies within the United Kingdom and the United States. As the Founder and one of the Benefactors of the Dill Faulkes Educational Trust, a UK registered charity, Dill also focuses on charitable activities.



Cameron Reynolds MBA, President & Group Chief Executive Officer - Cameron has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of public and private enterprises. Cameron was educated at the University of Western Australia receiving both a B.Com. and an MBA.



Terig Hughes, Group Chief Financial Officer – Terig is a seasoned finance professional with over twenty-five years of accounting, finance and business management experience gained through an international career spanning US, Europe and Asia. Terig received a Bachelor's degree in Accounting and Law from De Montfort University, Leicester, UK.



Gaetan Michel PhD, Chief Operating Officer – Gaetan has over 15 years' project management, manufacturing and operational experience at AAT (Advanced Array Technology), EAT (Eppendorf Array Technology), KitoZyme a global manufacturer of biopolymers of fungal origin and latterly Volition. Gaetan was educated at the University of Namur, Belgium receiving both a Bachelor of Science and a PhD.



Louise Batchelor, Chief Marketing and Communications Officer - Lou has more than 25 years of marketing, sales and leadership experience. Formerly Lou worked in various roles at Reckitt Benckiser including roles in Paris and New York. She holds a BA in Business Studies from Sheffield Hallam University.



Nick Plummer, Group General Counsel - Nick has over 25 years experience as a corporate and commercial lawyer, specializing in healthcare. Nick qualified with the international law firm, Ashurst, and has since worked in-house for companies such as Novacyt, Ark Therapeutics PLC and Patheon, which is part of Thermo Fisher Scientific.

高管团队



Dill Faulkes博士，执行董事会主席——Dill Faulkes作为英国和美国多家软件公司的创始人和首席执行官，拥有超过30年的创业和管理经验。作为英国注册慈善机构Dill Faulkes Educational Trust的创办人和受益人之一，Dill还致力于慈善活动。



Cameron Reynolds，工商管理硕士，总裁兼集团首席执行官——Cameron在新兴公司的管理，组织和战略规划方面拥有丰富的经验，并在公共和私营企业担任首席执行官、首席财务官以及非执行董事。Cameron在西澳大利亚大学获得商学学士和工商管理硕士学位。



Terig Hughes，集团首席财务官—Terig是一位经验丰富的财务专家，拥有超过25年的会计、财务和商业管理经验，其国际职业生涯横跨美国、欧洲和亚洲，在英国莱斯特的德蒙福特大学获得了会计和法律的学士学位。



Gaetan Michel博士，首席运营官 – Gaetan有超过15年的项目管理、生产和运营经验，曾任职于AAT (先进阵列技术)、EAT (Eppendorf阵列技术)、KitoZyme (全球真菌源生物聚合物制造商)，后来入职Volition，曾在那慕尔大学学习，获得了理学学士和博士学位。



Louise Batchelor，首席营销和传播官- Lou拥有超过25年的营销、销售和领导经验。曾在Reckitt Benckiser担任过各种职务，包括在巴黎和纽约任职。拥有谢菲尔德哈兰大学的商业研究学士学位。



Nick Plummer，集团总法律顾问 - Nick拥有超过25年的企业和商业律师经验，擅长医疗保健领域，在国际律师事务所Ashurst取得资格，此后在企业内部工作，如Novacyt、Ark Therapeutics PLC和Patheon，后者是赛默飞世尔科技的一部分。

Executive Team



Jake Micallef PhD MBA, Chief Scientific Officer - Jake is an experienced scientist with expertise in research and development and in the management of biotechnical companies, including manufacturing and establishing operations. He received his BSc and a PhD in Physical Chemistry from King's College London. In addition, he received his MSc in Chemical Pathology, and an MBA from Imperial College Management School.



Jasmine Kway PhD, Chief Executive Officer, Singapore Volition - Jasmine has a proven track record in achieving positive business results by developing strategic business alliances and identifying new markets. She has successfully commercialised and expanded companies into the Asian markets. Jasmine has a B.Eng and a PhD in Oceanography from the National University of Singapore.



Tom Butera DVM, Chief Executive Officer of VVDD – Tom is a Doctor of Veterinary Medicine with more than 40 years of experience in equine and small animal health in private practice, as well as extensive work in both business development and management of veterinary companies. He earned his Doctor of Veterinary Medicine from the University of Missouri Veterinary School, going on to serve as an Assistant Professor at Tufts University Veterinary School. Tom is an honorary member of the American Veterinary Medical Association and a licensed veterinarian in the Commonwealth of Massachusetts.



Heather Wilson-Robles DVM, Chief Medical Officer of VVDD – Heather is a well-established veterinary medical oncologist specializing in canine models of human cancer. Her research over the past 15 years has focused on improving canine models of pediatric and adult cancers and translating these findings to the mutual benefit of both species. Her basic research focuses on the identification and targeting of the tumor-initiating cells in osteosarcoma, melanoma and mammary/breast cancers in both canines and humans.



Gael Forterre MBA, Chief Commercial Officer - Gael has extensive experience investing in and scaling fast-growing companies, most recently as CEO of Path Inc. He is currently a non-executive board member of Integrated Wellness Holdings. Gael started his career as a hedge fund analyst in Paris and worked in a number of investment banking and more recently executive roles over fifteen plus years. Gael received a master's in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.

高管团队



Jake Micallef博士，工商管理硕士，首席科学官 - Jake是一位经验丰富的科学家，在研发和生物技术公司的管理（包括制造和建立运营）方面具有专业知识，获得了伦敦国王学院的理学学士学位和物理化学博士学位，还获得了化学病理学理学硕士学位和帝国大学管理学院的工商管理硕士学位。



Jasmine Kway博士，Singapore Volition首席执行官 - Jasmine在建立积极的商业成果方面有着良好的履历，通过建立战略性商业联盟和确定新市场来取得积极的商业成果。成功地将公司商业化并扩展到亚洲市场。拥有新加坡国立大学的海洋学学士学位和博士学位。



Tom Butera DVM, VVDD首席执行官 - Tom是一名兽医博士，在马匹和小动物健康方面有超过40年的私人执业经验，并在兽医公司的业务发展和管理方面有着广泛的工作经验，在密苏里大学兽医学院获得了兽医学博士学位，随后在塔夫茨大学兽医学院担任助理教授，是美国兽医协会的荣誉会员，也是马萨诸塞州联邦的执业兽医。



Heather Wilson-Robles DVM, VVDD首席医学官 - Heather是一位知名的兽医医学肿瘤学家，专门研究人类癌症的犬模型。在过去的15年中，专注于改善小儿和成人癌症的犬模型研究，并将这些发现转化为两种物种的共同利益。基础研究专注于鉴定和靶向犬和人的骨肉瘤、黑色素瘤和乳腺/乳腺癌中的肿瘤起始细胞。



Gael Forterre 工商管理硕士，首席商务官 - Gael在投资和扩大快速增长的公司方面有丰富的经验，最近担任了Path Inc.的首席执行官，目前担任Integrated Wellness Holdings的非执行董事。其职业生涯始于在巴黎担任对冲基金分析师，在15年以上的时间里，曾在多家投资银行工作，后来担任投资银行高管职务。Gael拥有巴黎第一大学的金融硕士学位，以及哥伦比亚商学院和伦敦商学院的双料工商管理硕士学位。

Executive Team



Jason Terrell MD, Chief Medical Officer & Chief Executive Officer of Volition America, Inc. - Jason has expertise in clinical medicine and in laboratory diagnostics in the areas of business development, clinical trials, regulatory affairs, and commercialization strategies. He was educated at Hardin-Simmon University where he graduated Summa Cum Laude, also receiving the Holland Medal of Honor. He received his MD from the University of Texas Medical School an affiliate of the MD Anderson Cancer Center.



Mark Eccleston PhD, MBA Chief Technology Officer - Mark is an enthusiastic and passionate biotechnology entrepreneur with over 20 years experience in the sector. He holds a PhD in Polymer Chemistry for biomedical applications and gained an MBA (entrepreneurship) from the University of Dundee in 2008.



Marielle Herzog PhD, Research & Development Director – Marielle is an epigeneticist with nearly 15 years research experience at the Institute of Genetics and Molecular and Cellular Biology (IGBMC), Strasbourg, the Laboratory of Cancer Epigenetics, Free University of Brussels and as the R&D director at Volition. She manages a team of project managers and coordinates several external academic collaborations as well as outsourced commercial R&D and clinical programs.



Theresa Kelly PhD, Chief Scientific Officer of Volition America, Inc. - Terry has over 10 years of experience in Epigenetics including developing novel technologies and seeing them through to commercialization. She previously was the R&D Director at Active Motif and the Global leader for custom assays and services and Agena Bioscience. She received her PhD from UCLA and did Post-doctoral training at USC's Norris Cancer Center where she studied epigenetic regulation in Cancer.



Rod Rootsart LLB, Corporate Secretary - Rod is an experienced legal and corporate secretary with over ten years experience in providing corporate, legal and administrative services to start-up companies. He previously served as corporate secretary for several junior mining companies in the United Kingdom. Rod received a LLB from the University of Western Australia.



Scott Powell PhD, EVP, Investor Relations & CFO of Volition America, Inc. - Scott has over 20 years of experience in the U.S. capital markets and investor relations. Scott worked for several years as an investment banker. He earned his B.S. in Business Administration from Bryant University and his MA and PhD degrees from Brown University.

高管团队



Jason Terrell医学博士，Volition America, Inc. 首席医学官兼首席执行官— Jason在业务发展、临床试验、法规事务和商业化策略领域的临床医学和实验室诊断方面拥有专业知识，在哈丁-西蒙大学受教育，获得拉丁文学位荣誉，并获得了荷兰荣誉勋章，从德克萨斯大学医学院安德森癌症中心的附属机构获得医学博士学位。



Mark Eccleston博士，工商管理硕士，首席技术官 - Mark是一位热情的生物技术企业家，在该领域拥有20多年的经验，拥有生物医学应用高分子化学博士学位，并于2008年获得了邓迪大学的工商管理硕士（创业学）学位。



Marielle Herzog博士，研发总监 – Marielle是表观遗传学家，在斯特拉斯堡的遗传与分子和细胞生物研究所（IGBMC）、布鲁塞尔自由大学癌症表观遗传学实验室拥有近15年的研究经验，并担任Volition研发总监，管理着一个由四名项目经理组成的团队，并协调数次外部学术合作以及外包的商业研发和临床计划。



Theresa Kelly博士，Volition America, Inc. 首席科学官—Terry在表观遗传学领域拥有10多年的经验，包括开发新技术并实现商业化，曾担任Active Motif的研发总监，以及定制分析和服务以及Agena Bioscience的全球负责人，获得了加州大学洛杉矶分校（UCLA）博士学位，并在南加州大学诺里斯综合癌症中心（Norris Cancer Center）进行了博士后培训，研究了癌症的表观遗传调控。



Rod Rootsart，法学士，工商秘书 - Rod是经验丰富的法律和公司秘书，在为初创公司提供公司、法律和行政服务方面拥有十多年的经验，曾在英国的几家初级矿业公司担任公司秘书。Rod获得了西澳大利亚大学的法学学士学位。



Scott Powell博士，Volition America, Inc. 投资者关系执行副总裁兼首席财务官 - Scott在美国资本市场和投资者关系方面拥有20多年的经验。曾担任投资银行家多年，获得了布莱恩特大学工商管理专业理学学士学位以及布朗大学的文学硕士和博士学位。

Thank you for your interest in Volition.
感谢您关注Volition

For more details, please visit www.volition.com
欲了解更多信息，请访问我们的网站www.volition.com